Table 1.
The characteristics of the included studies.
| Study/author name | JO25567 [12] | Kitagawa C [19] | Stinchcombe T [20] | NEJ026 [13] | RELAY [15] | CTONG1509 [14] | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Study phase | Phase II RCT | Phase II RCT | Phase II RCT | Phase III RCT | Phase III RCT | Phase III RCT | ||||||
| Study arms | Bev + Erl | Erl | Bev + Gef | Gef | Bev + Erl | Erl | Bev + Erl | Erl | Ram + Erl | Erl | Bev + Erl | Erl |
| No. of patients (n) | 75 | 77 | 6 | 10 | 43 | 45 | 112 | 112 | 224 | 225 | 157 | 154 |
| Median age, years | 67 | 67 | 73.5 | 72.5 | 65 | 63 | 67 | 68 | 65 | 64 | NR | NR |
| Male (n, %) | 30 (40%) | 26 (33.8%) | 1 (16.7%) | 3 (30%) | 12 (27.9%) | 14 (31.1%) | 41 (36.6%) | 39 (34.8%) | 83 (37.1%) | 83 (36.9%) | 60 (38.2%) | 58 (37.7%) |
| Never smoker | 42 (56%) | 45 (58.4%) | 4 (66.7%) | 8 (80%) | 25 (58.1%) | 23 (51.1%) | 65 (58%) | 64 (54.5%) | 134 (59.8%) | 139 (61.8%) | NR | NR |
| Former smoker | 9 (12%) | 6 (7.8%) | 2 (33.3%) | 2 (20%) | 14 (32.6%) | 15 (33.3%) | 6 (5.4%) | 7 (6.3%) | NR | NR | NR | NR |
| EGFR L858R (n, %) | 35 (46.7%) | 37 (48.1%) | 2 (33.3%) | 3 (30%) | 14 (32.6%) | 15 (33.3%) | 56 (50%) | 57 (50.9%) | 99 (44.2%) | 105 (46.7%) | 75 (47.8%) | 75 (48.7%) |
| ECOG PS 1 (n, %) | 32 (42.7%) | 36 (46.8%) | 4 (66.7%) | 3 (30%) | 19 (44.2%) | 26 (57.8%) | 48 (42.9%) | 42 (37.5%) | 108 (48.2%) | 106 (47.1%) | 132 (84.1%) | 137 (89%) |
| Adenocarcinoma (n, %) | 74 (98.7%) | 76 (98.7%) | 6 (100%) | 9 (90%) | NR | NR | 110 (98.2%) | 112 (100%) | 215 (96%) | 218 (96.9%) | 157 (100%) | 154 (100%) |
| Stage IIIB (n, %) | 1 (1%) | 0 | 0 | 1 (10%) | NR | NR | 8 (7.1%) | 8 (7.1%) | NR | NR | 4 (2.6%) | 6 (3.9%) |
| Stage IV (n, %) | 60 (80%) | 62 (80.5%) | 6 (100%) | 9 (90%) | 39 (90.7%) | 39 (86.7%) | 82 (73.2%) | 84 (75%) | 195 (87.1%) | 189 (84%) | 141 (89.8%) | 134 (87%) |
| Recurrence (n, %) | 14 (18.6%) | 15 (19.5%) | NR | NR | NR | NR | 22 (19.6%) | 20 (19.6%) | NR | NR | 12 (7.6%) | 14 (9.1%) |
| Brain metastases (n, %) | NR | NR | NR | NR | 11 (25.6%) | 14 (31.1%) | 36 (32.1%) | 36 (32.1%) | NR | NR | 44 (28%) | 47 (30.5%) |
| Treatment duration, median (days) | Bev:326 Erl:431 |
254 | NR | NR | Bev: 350 Erl: 405 |
364 | Bev: 308 Erl: 395 |
314 | Bev: 462 Erl: 551 |
377 | ||
Bev: bevacizumab; Erl: erlotinib; Ram: ramucirumab; 19del: EGFR exon 19 deletion; L858R: EGFR L858R mutation; ECOG PS: Eastern Cooperative Oncology Group performance status scores; NR: not reported.